Key Stats for Illumina Stock
- 52-Week Range: $79 to $156
- Current Price: $143
- Street Mean Target: $144
- Street High Target: $175
- Analyst Consensus: 8 Buys / 3 Outperforms / 6 Holds / 2 Underperforms / 1 Sell
- TIKR Model Target (Dec. 2030): $227
What Happened?
Illumina (ILMN), the dominant maker of gene-sequencing instruments that decode human DNA for clinical and research use, posted a Q1 result in late April that beat on every line and triggered a guidance raise.
Q1 revenue came in at $1.09 billion, up 4.8% year over year and $20 million above the midpoint of the company’s own guidance range, driven by stronger-than-expected NovaSeq X placements and clinical consumable demand.
The number that made the result undeniable: over 80 NovaSeq X instruments placed in the quarter, roughly 20 more than in Q1 of the prior year and well above the company’s targeted range of 50 to 60 per quarter.
Jacob Thaysen, Chief Executive Officer, stated on the Q1 2026 earnings call that “we are off to a great start in 2026 with Q1 revenue, margin and EPS all coming in above our guidance range,” and raised the full-year revenue outlook to $4.52 billion to $4.62 billion.
Alongside the earnings beat, Illumina CEO Jacob Thaysen joined President Trump’s trade delegation to Beijing, a trip that raised expectations of an easing of China’s restrictions on ILMN sequencer exports, a market where China revenue has declined from roughly $502 million in 2021 to roughly $242 million in 2025.
Evercore ISI noted that the delegation’s presence could hint at smoother processes for Chinese customers purchasing Illumina instruments, calling it an “incremental positive” with the potential to turn China from a headwind into a tailwind.
Illumina also authorized $1.5 billion in additional share repurchases, layering a capital return program on top of the operational inflection and giving the investment case a third driver beyond clinical growth and China recovery.
Wall Street’s Take on ILMN Stock
The Q1 beat shifts the conversation from “can Illumina stabilize” to “how fast does the clinical business compound,” and that question is where the investment case gets interesting.
ILMN’s normalized EPS came in at $1.15 in Q1, up roughly 19% year over year, with consensus calling for around $1.22 for Q2 and around $5.22 at the full-year midpoint, a growth trajectory anchored to the NovaSeq X installed base generating recurring consumable revenue as clinical customers expand sequencing-intensive applications.
Wall Street carries 8 Buys, 3 Outperforms, 6 Holds, 2 Underperforms, and 1 Sell, with a mean price target of $143.63 against the current price of $142.54, essentially implying the stock is fairly priced at current levels absent a new catalyst.
The spread between the $95 low target and the $175 high target is wide enough to signal a genuine debate: bears point to research and applied consumables declining around 12% in Q1, while bulls see the China re-entry as a binary event that could add a full revenue tier if restrictions ease further.
Research and applied revenue declines mid- to high single digits on the company’s own guide, and if NIH funding uncertainty persists into the second half, the market’s confidence in a consumables reacceleration could weaken before China upside materializes.
Q2 earnings, expected to show around $1.12 billion to $1.14 billion in revenue and around $1.20 to $1.25 in normalized EPS, will be the first test of whether the clinical momentum that drove Q1 upside can absorb an instrument mix headwind and the full quarter of SomaLogic integration costs.
What Does the Valuation Model Say?
The TIKR model prices ILMN at a mid-case target of around $227, implying roughly 59% upside from the current price of $143, driven by a revenue CAGR assumption of around 6% and a net income margin expanding from the current 8.9% toward around 23% by 2030 as the NovaSeq X consumables flywheel compounds and SomaLogic losses shrink.
With a mid-case IRR of around 9% and the 10-year historical revenue CAGR at 6.9%, Illumina stock appears undervalued against a clinical growth trajectory that has now posted 20% ex-China consumable growth for two consecutive quarters.
The central tension: the model’s mid-case return is built on execution that the last decade’s margin history says is achievable, but the path runs through a China recovery and a research market rebound that have not yet arrived.
What Has to Go Right
- China re-entry accelerates: Beijing’s November 2025 lifting of the export ban established the legal pathway; CEO participation in the Trump-Xi summit suggests political momentum that could take China from a $242 million drag back toward the $502 million peak.
- Clinical consumables sustain 20% growth: two consecutive quarters of 20% ex-China clinical consumable growth, with 76% of clinical volume now on the NovaSeq X and management targeting over 80% to 85% by year-end, reducing the pricing transition headwind.
- SomaLogic integration delivers: the January 2026 acquisition adds proteomics exposure to Illumina’s platform; management targets margin improvement throughout 2026 as the acquired cost base is absorbed.
- NovaSeq X backlog converts: performance obligations up more than 20% year over year per the Q1 10-Q filing, and Q2 placements expected near Q1’s 80-unit pace, setting up a consumables revenue ramp in the second half.
What Could Go Wrong
- Research market stays frozen: NIH funding uncertainty kept research and applied consumables down around 12% in Q1; if grants do not translate to spending through 2026, the revenue recovery built into the high-case model does not materialize.
- China optionality remains optionality: ILMN remains on China’s “unreliable entity” list, which still requires government approval for Chinese buyers; summit goodwill does not guarantee regulatory removal, and the market may be pricing a recovery that is still one step away.
- Margin expansion stalls: the Q2 guide carries around 22% operating margins against a full quarter of SomaLogic and higher instrument mix, narrowing the cushion; if inflationary headwinds persist beyond Q3, the 500 basis point margin expansion target by 2027 faces compression risk.
Should You Invest in Illumina, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Illumina, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Illumina, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ILMN stock on TIKR for Free →
